TransEnterix JPM 2016 - PDF With Video Links

7/25/2019 TransEnterix JPM 2016 - PDF With Video Links

1/23

TransformingSurgical Robotics34thAnnual J.P. Morgan Healthcare Conference

January 14, 2016


2/23

Forward Looking Statements

This presentation includes statements relating to TransEnterixs current regulatory and

commercialization plans for our products. These statements and other statements regaplans and goals constitute "forward-looking statements" within the meaning of Section Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and arqualify for the safe harbor from liability established by the Private Securities Litigation R1995. Such statements are subject to risks and uncertainties that are often difficult to pbeyond our control, and which may cause results to differ materially from expectationscould cause our results to differ materially from those described include, but are not limthe commercialization of the ALF-X surgical robotics system will be successful, whetheSystem's 510(k) application will be cleared by the U.S. FDA, the pace of adoption of ou

surgeons, the success and market opportunity of our products, the effect on our busineand new regulatory requirements and other economic and competitive factors. For a dimost significant risks and uncertainties associated with TransEnterix's business, pleasfilings with the Securities and Exchange Commission (SEC), including our Quarterly R10-Q filed on November 9, 2015 and other filings we make with the SEC. You are caut

place undue reliance on these forward looking statements, which are based on our expthe date of this presentation and speak only as of the origination date of the presentatiundertake no obligation to publicly update or revise any forward-looking statement, wh

of new information, future events or otherwise.


3/23

TransEnterix: TRXC

Focus: Surgical Robotics

Significant addressable market opportunity Robotics growing but minimally penetrated

Compelling Product Portfolio SurgiBot single-port platform

ALF-X multi-port platform

Upcoming milestones ALF-X sales commence Q1 16

SurgiBot FDA clearance Q1 16


4/23

Surgical Robotics Market is Poised fGrowth

in 2021

in 2014

Continued mand new entgrow abdomrobotic surgsignificantly

Source: Abdominal Surgical Robots Market Shares, Strategies, and Forecasts, Worldwide, 2015 to 2021WinterGreen Research, December 2015

Abdominal Robotic Surgery Market Size

$2.2 Billion

$10.5 Billion


5/23

Why Robotics?

Benefits ofSurgicalRobotics

Enhanced

precision anddexterity

Increased

surgeoncontrol

Improved

surgeonergonomics

Advavisual


6/23

Robotic Adoption Remains Low

U.S. Europe

Robotics is a small percentage of total procedures

Reasons why: Trade-offs and economics

Source: Millennium Research Group, US and EU Laparoscopic Devices Report 2014

Surgical Procedures by Type, 2014


7/23

Strategy to Increase Robotic Ado

Growth Drivers:Build on success of laparoscopy

Compelling economic value to hospitals

Innovative technology that addresses trade-of

Both SurgiBot & ALF-X are

designed to meet these needs


8/23

Traditional laparoscopy remains thedominant form of minimally invasivesurgery

Over 6 million laparoscopic proceduresacross US and CE Mark countries*

Surgeons are experienced withapproach, technique and instrumentmotion

Build on the Success of Laparos

*Data source: Millennium Research Group Laparoscopic Devices 2014 Report.

Both SurgiBot & ALF-X build on the success of lap


9/23

Limitations of current robotic systems

Need for Compelling Economic V

High robotic capital costs limits broaderhospital adoption

Robotic procedures utilize existinglaparoscopic reimbursement codes

High robotic procedure costs limitsbroader procedural adoption

Both SurgiBot & ALF-X are designed toprovide compelling economics


10/23

Need to Address Trade-offs

Learning curve

No haptic feedback

Disengagement with surgical field

Requires special trocars that increase typical incision size

Limits ability to reposition patient

Camera movement requires disengagement of instruments

Limitations of current robotic systems


11/23

TRXC Surgical Robotics Portfoli

The ALF-X has been granted CE Mark. Neither SurgiBot nor ALF-X has been cleared by the FDA for sale in the U.S.


12/23

The SurgiBot System is currently in development

SurgiBot Single-port Robotic Pla

3DHD VSurgiBot


13/23

SurgiBot Patient-side Robotic Pl
https://vimeo.com/150378179https://vimeo.com/150378179


14/23

SurgiBot System: Builds on Success of La

Surgeon Scrubbed in Sterile Field

Laparoscopic motion

Utilizes familiar instrument

triangulation through single port


15/23

Attractive capital system pricing

Expands robotics to more facilities

Technology that addresses trade-offs

Improved ergonomics

Surgeon able to maintain comfortable hand position

Tactile feedback Surgeon directly drives instruments

Enhanced vision

3DHD controlled by surgeon

SurgiBot System: Addressing Economics Trade-offs


16/23

ALF-X Multi-port Robotic Platfor


17/23

ALF-X System: Building on Laparoscopy Addressing Trade-offs

Laparoscopic Motion

Leverage existing infrastructure

Utilize current trocars

Ease of patient repositioning with current O.R. bed

Ports allow both robotic and traditional lapinstruments

Haptic feedback

Enhanced vision

3DHD controlled via eye tracking

Fast and simple set-up


18/23

ALF-X Fast and Simple Setup


19/23

ALF-X System: Compelling Econom

Disruptive robotic per-procedure pricingmodel Reusable instruments

Minimal disposables per case

Broad instrument offering

22 instruments

Select wristed instruments

Access to robotics with operational costssimilar to many traditional laparoscopic

procedures


20/23

Key Recent and Future Mileston

2015 2016 2

EXAMPLE TEXT QQ3Q2

SurgiBot FDA Submission Acquired ALF-X RoboticSystem

Appointed US CommercialLeadership

Appointed IntCommercial L


21/23


2016 20172015

Q2Q1

ALF-X Sales Commence, Commercialteam expansion

SurgiBot US Regulatory Clearance

Complete Acquisition Integration

Q2 - SurgiBot US Commer


22/23


201720162015

ALF-X US Commercial Launch

Commercial Launch into Additional International Markets


23/23

Focus: Surgical Robotics

Significant addressable market opportunity Robotics growing but minimally penetrated

Compelling Product Portfolio SurgiBot single-port platform

ALF-X multi-port platform

Upcoming milestones ALF-X sales commence Q1 16

SurgiBot FDA clearance Q1 16

TransEnterix: TRXC

Documents

TransEnterix JPM 2016 - PDF With Video Links